Company Description
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers.
It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
The company’s lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC).
It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H.
to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma.
UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
| Country | United States |
| Founded | 2004 |
| IPO Date | May 4, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 201 |
| CEO | Elizabeth Barrett |
Contact Details
Address: 400 Alexander Park Drive, 4th Floor Princeton, New Jersey 08540 United States | |
| Phone | 646 768 9780 |
| Website | urogen.com |
Stock Details
| Ticker Symbol | URGN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001668243 |
| CUSIP Number | M96088105 |
| ISIN Number | IL0011407140 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Elizabeth A. Barrett | President, Chief Executive Officer and Director |
| Dr. Mark P. Schoenberg M.D. | Chief Medical Officer |
| Vincent I. Perrone | Senior Director of Investor Relations |
| Bryon Wornson | Executive Vice President of Talent, Advocacy and Communications |
| Dr. Marina Konorty Ph.D. | Executive Vice President of Research and Development and Technical Operations |
| James Ottinger R.ph. | Executive Vice President of Regulatory Affairs and Quality |
| Dr. Polly A. Murphy D.V.M., M.B.A., Ph.D. | Chief Business Officer |
| Michael J. Louie M.D., M.P.H., M.Sc. | Senior Vice President of Medical Affairs and Clinical Development |
| David Lin | Chief Commercial Officer |
| Gil Hakim | Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 18, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 6, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |